Clorox Could Crowned Dividend King by 2027: What Investors Should Know
Clorox has stacked a long streak of dividend increases, but reaching 50 years could hinge on a crucial strategic shif...
Articles — Page 1525
Chewy Down This Year: A Smart Buy for Long-Term Investors
Chewy has faced a rough year, with shares falling and growth challenges ahead. Yet, a closer look under the hood show...
Turning Point Brands Stock Shines: A Thursday Rally
Turning Point Brands stock captured attention with a double-digit sales lift and solid earnings signs that stunned ma...
Mercadolibre Stock Crashed Today: Why the Drop Happened
Mercadolibre stock crashed today after investors digested a quarter that showed rising revenue but softer earnings. T...
Got $50,000? Amazon Stock Still Could Build Wealth
A $50,000 investment can feel like a fork in the road. This guide explains why Amazon stock still has the potential t...
SEC Looks at 1990s Crypto Markets for Innovation Pathway
The SEC outlines a two-stage approach to on-chain trading, echoing lessons from the 1990s as it weighs how crypto ven...
This Economist Studied Years: Recessions Are Random
A leading economist argues that recessions aren’t predictable cycles after studying four centuries of data, urging ho...
Here's Shares Agios Pharmaceuticals: 2026 Outlook and Rally
Biotech investors watched Agios Pharmaceuticals spark a notable rally after key quarterly results and a strong Aqvesm...
Axsome Therapeutics Stock Jumped: April Rally and What It Means for Investors
Axsome Therapeutics rode a powerful April rally driven by Auvelity performance and pipeline momentum. This article br...
This Dividend King's Yield Near 3%: Is It a Buy Now?
Income investors are eyeing a familiar Dividend King delivering a near-3% yield. This article breaks down what that s...
Pfizer Stock: Still Priced — a Long-Term Opportunity for Investors
Pfizer's stock has lagged since 2021, but the story isn’t over. This guide breaks down why pfizer stock: still priced...
Lilly Just Announced Fantastic News for Shareholders
Eli Lilly is delivering big news for investors. The rallying force behind recent gains comes from GLP-1 drugs, manufa...